Page last updated: 2024-08-17

spironolactone and satavaptan

spironolactone has been researched along with satavaptan in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bruha, R; Dudley, F; Ginès, P; Terg, R; Watson, H; Wong, F; Zarski, JP	1
Angeli, P; Bernardi, M; Gines, P; Gow, P; Horsmans, Y; Minini, P; Watson, H; Wong, F	1
Accordino, S; Cazzaniga, M; Salerno, F	1

Trials

2 trial(s) available for spironolactone and satavaptan

Article	Year
Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study. Alimentary pharmacology & therapeutics, 2010, Volume: 31, Issue:8 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Body Weight; Diuretics; Double-Blind Method; Drug Combinations; Female; Furosemide; Humans; Liver Cirrhosis; Male; Middle Aged; Morpholines; Prospective Studies; Spiro Compounds; Spironolactone; Treatment Outcome	2010
Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. Journal of hepatology, 2010, Volume: 53, Issue:2 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Combined Modality Therapy; Creatinine; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyponatremia; Liver Cirrhosis; Male; Middle Aged; Morpholines; Paracentesis; Secondary Prevention; Spiro Compounds; Spironolactone; Thirst; Treatment Outcome	2010

Article

Year

Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study.

Alimentary pharmacology & therapeutics, 2010, Volume: 31, Issue:8

Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Body Weight; Diuretics; Double-Blind Method; Drug Combinations; Female; Furosemide; Humans; Liver Cirrhosis; Male; Middle Aged; Morpholines; Prospective Studies; Spiro Compounds; Spironolactone; Treatment Outcome

2010

Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis.

Journal of hepatology, 2010, Volume: 53, Issue:2

Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Combined Modality Therapy; Creatinine; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyponatremia; Liver Cirrhosis; Male; Middle Aged; Morpholines; Paracentesis; Secondary Prevention; Spiro Compounds; Spironolactone; Thirst; Treatment Outcome

2010

Other Studies

1 other study(ies) available for spironolactone and satavaptan

Article	Year
May vaptans contribute to the treatment of refractory ascites? Journal of hepatology, 2010, Volume: 53, Issue:2 Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Combined Modality Therapy; Diuretics; Dose-Response Relationship, Drug; Humans; Hyponatremia; Liver Cirrhosis; Morpholines; Paracentesis; Spiro Compounds; Spironolactone; Treatment Outcome	2010